title: Prolonged disease-free survival after ablative chemoradiotherapy and autologous bone marrow transplantation in adult malignant lymphoma.
abstract: From June 1983 to December 1991, 21 adult patients with intermediate or high-grade malignant lymphoma (ML) were treated by ablative chemoradiotherapy, including vincristine, cytosine arabinoside, BCNU and cyclophosphamide plus total lymphoid or body irradiation with boost irradiation over bulky and original tumor areas (Hd-VCCA+TL(B) I) together with autologous bone marrow transplantation (ABMT). Five patients were in advanced stage, 2 in drug-resistant relapse, 6 in drug sensitive relapse, 6 in first complete remission (CR1) and 2 in CR2. One with marrow involvement at ABMT. The 8-year disease-free survival after ABMT in patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) in 89% and 63%, respectively, with a median follow-up up to 34 months. This study demonstrated that our Hd-VCCA+TL(B) I regimen and ABMT performed early in CR or drug-sensitive relapse of adult poor prognosis lymphoma, may potentially cure more than 70% of them. The toxicity of the present treatment is tolerable. The results confirm the value of ABMT in the treatment of adult ML, and suggest that it is necessary to purge the residual tumor cells in the bone marrow at ABMT in patients with marrow infiltration, or lymphoblastic lymphoma.
authors.affiliation: Department of Hematology, Lanzhou PLA General Hospital.
authors.forename: W M
authors.initials: WM
authors.lastname: Da
authors.forename: J T
authors.initials: JT
authors.lastname: Zhong
authors.forename: Y
authors.initials: Y
authors.lastname: Liu
authors.forename: Y S
authors.initials: YS
authors.lastname: Huang
authors.forename: H
authors.initials: H
authors.lastname: Bai
authors.forename: X X
authors.initials: XX
authors.lastname: Wu
authors.forename: Y X
authors.initials: YX
authors.lastname: Ou
authors.forename: C B
authors.initials: CB
authors.lastname: Wang
authors.forename: S F
authors.initials: SF
authors.lastname: Xu
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016465:Bone Marrow Purging; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D014750:Vincristine / Q000008:administration & dosage; D014916:Whole-Body Irradiation
chemical_list: D003561:Cytarabine; D014750:Vincristine; D008130:Lomustine; D003520:Cyclophosphamide